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Abstract 
Background: The Lémann Index was recently developed to evaluate the 
cumulative bowel damage in patients with Crohn's disease. 
Aims: To search for a difference between adalimumab and azathioprine to halt 
the progression of bowel damage in active Crohn's disease, using the Lémann 
Index. 
Methods: A single-centre, retrospective study was conducted. Patients with 
Crohn’s disease were included if they had colonoscopy and magnetic 
resonance enterography performed within 4 months from the start of 
adalimumab or azathioprine, and repeated after 12 months of therapy. Primary 
outcome was reached if the increase of Lémann Index after 12 months of 
treatment was < 0.3, the drug was not stopped, and the use of systemic 
steroids was continued for no more than 3 months.     
Results: Ninety-one patients were enrolled, 31 (34.1%) of them treated with 
adalimumab and 60 (65.9%) with azathioprine. Sixty-seven percent of patients 
treated with adalimumab reached the primary outcome compared to 28.3% of 
patients treated with azathioprine (p = 0.0006). The Lémann Index in the group 
on adalimumab therapy decreased after 12 months (from 9.9 to 8.8), while in 
the group on azathioprine therapy it increased (from 7.7 to 8.8). 
Conclusion: Treatment with adalimumab halts the progression of bowel damage 
in Crohn's disease while that with azathioprine does not. 
 
Key Words: Anti-TNF; Colonoscopy; Magnetic resonance enterography; Small 
intestine; Thiopurine 
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1 Introduction: 
Crohn's disease (CD) is a chronic disease characterized by different patterns 
including chronically active disease, intermittent disease and disease with 
remission periods over years. Considering the behaviour, CD at the onset is 
generally inflammatory, but later it turns into a fibrostenotic and fistulising 
pattern [1]. 
   The Lémann Index (LI) is a recently developed score, aiming to stage CD by 
calculating the cumulative bowel damage (CBD), even in absence of clinical 
and biochemical activity [2]. In fact, the LI incorporates clinical, surgical, 
endoscopic and radiological findings of all segments of the gastrointestinal tract 
into a single score. The progression of bowel damage is defined as LI increase 
> 0.3 points during a period of 12 months [3]. 
   There are still few studies in literature focusing on the course of LI following a 
therapy with biological or immunosuppressive agents. Two recent clinical trials 
have demonstrated the significant halt of CBD progression in a subgroup of CD 
patients after 12 months of treatment with an anti-tumor necrosis factor (TNF) 
drug (p = 0.007 and p = 0.043, respectively) [4,5]. 
   The aim of our study was to evaluate, using the LI, for the first time in 
literature, the difference of efficacy between adalimumab and azathioprine 
therapies, in halting CBD progression among patients with active CD. 
    
2 Material and methods:  
In this single-centre, retrospective study, consecutive medical records of 
patients with CD diagnosis, selected from the database of the inflammatory 
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bowel disease (IBD) Unit of San Giovanni Antica Sede-Molinette Hospital, 
Turin, Italy, were analysed. 
   The inclusion criteria were: 
- CD diagnosis confirmed according to ECCO guidelines [6];   
- At least one year of follow-up available; 
- Start of azathioprine or adalimumab therapy because of active CD; 
- Colonoscopy and magnetic resonance enterography (MR-E) performed 
at T0 (within 4 months before starting the drug, according to the routine 
protocol of our centre). In addition, esophagogastroduodenoscopy (EGD) 
and/or pelvic MR performed if clinically necessary; 
- Repetition at T1 (12 months +/- 2 months after the start of the treatment) 
of the instrumental examinations carried out at T0. 
 
   The exclusion criterion was: 
- To be treated with combination therapy with azathioprine and 
adalimumab. 
 
   The choice between azathioprine and adalimumab was made, case by case, 
through clinical judgment of the 30-years IBD expert physician of the team 
(M.A.), mainly according to ECCO guidelines [6]. In practice, steroids-
dependent patients were treated with azathioprine while steroid-refractory or -
intolerant or azathioprine-failure patients were treated with adalimumab; 
patients with perianal disease were treated with adalimumab. 
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   A numerical identification code was associated to each patient and a 
database was compiled with the collected information of each subject, reporting 
the following data:  
- Personal data: age, gender, year of birth, smoking status; 
- Clinical history: age at diagnosis, age at the start of drug treatment, years of 
disease, disease location; 
- Inflammatory indexes and clinical activity: C-reactive protein (CRP), Harvey-
Bradshaw index (HBI); 
- LI (calculated by us, how reported in all studies focusing on this index); 
- Presence of perianal disease; 
- Instrumental examinations: colonoscopy, MR-E, EGD, pelvic MR;  
- Therapy (duration and dosage): adalimumab, azathioprine, previous therapy 
with biological drug, dose-escalation of the biological drug, use of 
corticosteroids; 
- Surgical history. 
 
   Primary outcome:  
- To compare the percentage of patients in whom the treatment with 
azathioprine or that with adalimumab halted the progression of CBD, 
defined as an increase of LI < 0.3 in 12 months, without stopping the 
drug and without having used systemic corticosteroids for a period > 3 
months. 
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   Secondary outcomes: 
- Evaluation of the progress of LI from 0 to 12 months in patients who used 
one of the two drugs; 
- Correlation of the primary outcome with: years of disease before the start 
of the drug therapy, gender, smoking habits, previous intestinal 
resection, previous biological therapy, presence of perianal disease. 
- According to Pariente et al. [2], evaluation of the progress in the following 
subcategories of LI: upper tract (U), small bowel (S), colon / rectum (C) 
and anal region (P). Each tract was further divided into segments: 3 
segments for the upper digestive tract (oesophagus, stomach, and 
duodenum), 6 for the colon/rectum (cecum, ascending colon, transverse 
colon, descending colon, sigmoid colon, and rectum), and 1 for the anus.  
 
Focusing on the small bowel, each lesion within 20-cm length was considered 
to represent one segment, and the number of segments was capped at 20. For 
each organ, surgical procedures were defined in the protocol by grade of 
severity on an ordinal scale ranging from 0 (none) to 3 (resection). Stricturing 
and penetrating lesions were defined and illustrated in the protocol by grade of 
severity on an ordinal scale, ranging from 0 (none) to 3 (maximal) for diagnostic 
method. The most severe surgical procedure for each segment was assessed 
on the basis of medical history. Stricturing and penetrating lesions of maximal 
severity were assessed at each segment with the appropriate imaging 
techniques; for example, for stomach, these lesions were determined separately 
at each examination, using MRI, CT scan if available, and EGD. The rounded 
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coefficients that were applied to the number of segments with stricturing and 
penetrating lesions of each severity grade, in order to calculate the predicted 
organ index, are reported in the original paper [2]. 
 
2.1 Statistics 
Considering the continuous variables normally distributed, the arithmetic mean 
was calculated; for those not normally distributed, the transformation into a 
logarithmic scale was performed and then the geometric mean was calculated, 
otherwise the median was calculated. In case of continuous variables normally 
distributed or normally distributed after logarithmic transformation, the 
independent samples t-test was used to compare the means of two 
independent samples. As for continuous variables, not normally distributed 
despite the logarithmic transformation, the Mann-Whitney test was performed. 
The chi-square test was used to compare two groups of categorical variables. 
The Wilcoxon test was performed to compare the trend of paired samples for 
non-normal continuous variables despite logarithmic transformation. The paired 
t-test was used to compare the trend of paired samples for continuous variables 
distributed in a normal manner or if they were normally distributed after 
logarithmic transformation. The multivariate analysis was performed applying 
the logistic regression test. The results with p < 0.05 were considered 
statistically significant. 
   The statistical analysis was performed with MedCalc Statistical Software 
version 18.9.1 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2018). 
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2.2 Ethical considerations 
The study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki (6th revision, 2008). The study protocol was approved by the Ethical 
Committee “A.O.U. Città della Salute e della Scienza di Torino - A.O. Ordine 
Mauriziano - A.S.L. Città di Torino” on October 4, 2018 (code: 0098528).  
 
3 Results: 
The medical records of 300 patients, visited between January and April 2019, 
were analysed. Two hundred and nine patients were excluded from the study 
because they did not meet the inclusion criteria, or they met the exclusion 
criteria (Figure 1). 
 
Figure 1. 
 
Thus, 91 patients were included in the study. The clinical characteristics of this 
cohort is shown in Table 1.  
 
Table 1. 
 
Geometric mean of CRP was 7.0 mg/L, 95% confidence interval (CI): 5 – 9,8 
mg/L; median HBI was 6 (mild clinical activity), 95%CI: 5 – 8 (mild – moderate 
clinical activity). 
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   Of the 91 patients included in the study, 60 (65.9%) were treated with 
azathioprine and 31 (34.1%) with adalimumab. The comparison between the 
clinical characteristics of these two groups is shown in Table 2. 
 
Table 2. 
 
Regarding LI at T0, its median in patients treated with adalimumab was 9.9 
(95%CI: 3.2 - 15.8) versus 7.7 (95%CI: 3.7 - 11.5) in those treated with 
azathioprine (p = 0.734). The CBD before starting the therapy was comparable 
in the two groups. 
   During the 12 months of follow-up, two patients (6.5%) stopped adalimumab 
and 16 patients (26.7%) stopped azathioprine due to side effects or primary 
failure. Three patients in the adalimumab group (9.7%) underwent to dose 
escalation every week. 
   Twenty-one (67.8%) of the 31 patients treated with adalimumab reached the 
primary outcome versus 17 patients (28.3%) out of 60 in the azathioprine group 
(p = 0.0006) (Figure 2). 
 
Figure 2. 
 
LI score, in patients treated with adalimumab, did not progress in a statistically 
significant manner during the year of therapy (from 9.9 at T0 to 8.8 at T1, p = 
0.669) (Figure 3).  
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Figure 3. 
 
In the azathioprine-treated group the LI score progressed from 7.75 at T0 to 
8.80 at T1 (p = 0.074) (Figure 4). 
 
Figure 4. 
  
Regarding the subcategories of LI, the progression during the 12 months of 
therapy in the two groups (S and C) is reported in Table 3. 
 
Table 3. 
 
The analysis on the S subcategory showed that the LI at T0 and at T1 remained 
unchanged (1.30) among patients treated with adalimumab (no progression of 
damage occurred). On the other hand, in the group treated with azathioprine, an 
increase in the LI of 0.5 points was observed after 12 months with a statistical 
difference (p = 0.03). Focusing on the C segment, the value of the LI among 
patients treated with adalimumab decreased from 5.8 (T0) to 4.4 after one year 
(p = 0.899) while in the group treated with azathioprine the score did not change 
over time (5.8 at T0, 5.8 at T1, p = 0.181) 
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   We also investigated the effect of possible predictors of drug response. The 
results are reported in Table 4. 
 
Table 4 
 
In multivariate analysis, none of these predictors reached statistical significance 
(p > 0.097). 
 
4 Discussion: 
CD is characterized by a persistent transmural inflammatory with consequent 
CBD which progresses over time even in patients with apparent clinical 
remission of symptoms [7]. In the past, the main outcome of medical therapies 
for CD was the clinical remission, intended solely as a resolution of symptoms, 
while currently the objectives are much more complex, including histological 
remission and halting the progression of CBD [8].  
   Our study demonstrated that adalimumab achieved a greater success than 
azathioprine in halting the progression of CBD, in avoiding dropping out of 
therapy for side effects and in reducing the assumption of corticosteroid for 
more than 3 months during the study period (p = 0.0006). This figure is relevant  
considering that patients treated with adalimumab had a longer history of 
disease than those treated with azathioprine (13 years versus 5 years) (p = 
0.056), and the percentage of patients previously treated with biological drugs, 
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a possible factor of non-response, was higher (16.1% versus 5%, respectively) 
(p = 0.078) [9]. 
   Our results are in line with the data of Bodini et al. [8] however, these authors 
selected patients in clinical remission and did not include specifically an 
adalimumab-treated group. 
   For the first time in the literature, we compared the efficacy of adalimumab 
versus azathioprine in the ability to halt the progression of damage in the four 
categories into which the gastrointestinal tract has been divided (U, S, C and P). 
Adalimumab therapy has prevented the damage progression in the small bowel 
(the analysis on the S subcategory showed that the LI at T0 and at T1 remained 
unchanged with LI = 1.30), while azathioprine did not (an increase in the LI of 
0.5 points was observed after 12 months with a statistical difference, p = 0.03). 
Focusing on the C segment, the value of the LI among patients treated with 
adalimumab did not change significantly neither for adalimumab (p = 0.899), nor 
for azathioprine (p = 0.181). From these results it can be hypothesized that both 
adalimumab and azathioprine halt the damage progression in the colon / 
rectum. It was not possible to carry out the comparison in the subcategories U 
and P due to the low sample size of patients with damage in these locations.  
   We subsequently investigated whether potential predictive factors were 
related to the achievement of the primary outcome. The years of disease at the 
beginning of treatment were not a predictor of response either for adalimumab 
(p = 0.526), or for azathioprine (p = 0.324). The difference between the years of 
disease before the start of azathioprine (5 years) or adalimumab (13 years) was 
at the limit of statistical significance (p = 0.056). This could be due to the real-
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life design of our study, in which azathioprine was the first choice in steroid-
dependent patients, while adalimumab was prescribed in azathioprine-failure 
patients, in steroid-refractory or -intolerant patients or in those affected by 
perianal disease. Focusing on gender, there was a general tendency to a 
greater response among females for both drugs: this implies that gender does 
not correlate with the therapeutic choice. Being an active smoker did not 
influence the achievement of the primary outcome in the adalimumab group 
while in the azathioprine group a tendency towards a favourable response was 
observed in not active smokers (34.4%) compared to active smokers (21.4%). 
Focusing on surgical history, among patients treated with adalimumab the 
response was higher in those never operated compared with those who had a 
previous history of surgery (p = 0.059); on the contrary, in the azathioprine 
group, the drug appeared to have a slight tendency to be more effective in 
patients with history of at least one surgical resection (30.8% versus 26.4%). A 
trend, at the limit of significance (p = 0.056), to reach a favourable primary 
outcome, among patients with history of perianal disease, was observed in the 
adalimumab group while in the azathioprine group a double response rate was 
found (34.1% versus 15.8%) in patients without history of perianal disease. 
Finally, in the group treated with adalimumab, previous therapy with biological 
drugs did not represent a negative prognostic factor of response (p = 0.690).  
   From the study also emerged that 25% of patients treated with azathioprine 
suspended the drug because of side effects or primary failure versus 6% of 
those on adalimumab therapy. Hence, adalimumab had a much better safety 
and handling profile than azathioprine. 
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   Conversely, it should be noted that the evaluation of the efficacy of 
azathioprine in a single year can invalidate the results in absolute terms, since, 
from a clinical point of view, the 12-month period may not be sufficient to 
observe a full therapeutic response of the immunosuppressant [10], permitting 
only to demonstrate a lack of worsening of the CDB (which should be the 
minimal target to continue azathioprine); in fact, a more objective evaluation of 
the efficacy of azathioprine could be performed only 2-3 years after the 
beginning of the drug. 
   Furthermore, the different economic impact on the health system deserves to 
be discussed with respect to the two pharmacological treatments. On average, 
in Italy adalimumab therapy has an annual cost of about € 2500-3000 per 
patient compared to € 200-250 with azathioprine [11]. 
   The retrospective design is the major limitation of our study. However, it 
should be considered that the clinical characteristics of the two groups (included 
the CBD and so the state of disease progression) are not statistically different (a 
propensity-score analysis would not add benefit). Furthermore, the monocentric 
nature of the study, in which only one clinician (M.A.) gave indications to 
instrumental examinations and therapy to all patients, improves the 
homogeneity of the study. The use of MR-E did not induce a selection bias 
because in our centre all patients with CD of small bowel candidate to biologic 
drugs undergo to MR-E before starting this therapy and one year after. Another 
critical aspect is that not all the instrumental examinations indicated by the LI 
were performed in all patients; however, in the case of EGD and of pelvic MR, 
both literature and clinical practice suggest that these diagnostic methods 
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should be performed only in symptomatic patients [6]. Finally, the sample size 
was not very large, but this is the first study comparing, as primary outcome, 
adalimumab with azathioprine in halting CBD progression in active CD and it 
showed to have the statistical power to reach the primary outcome (p = 0.0006). 
    
5 Conclusions:  
In conclusion, adalimumab appears to have better therapeutic efficacy than 
azathioprine in halting the progression of CBD, assessed with LI, in patients 
with active CD. Considering the different mechanism of action and the lower 
cost of azathioprine, its role can still be hypothesized in patients with colonic 
involvement and without perianal disease. Adalimumab, on the other hand, is 
absolutely preferred in patients with CD located only in the small bowel or with a 
history of perianal disease. The data of our study deserve to be confirmed by 
prospective studies with larger sample size.  
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Table 1. Clinical characteristics of the included patients 
Parameter Value 
Age at the beginning of the drug (mean) 41.5 years (range: 15-75 years) 
Years of disease before drug starts 
(median) 
5 years, 95%CI: 4 - 9.3 
Number of surgeries 
None: 51 patients (56.0%) 
1 resection: 22 patients (24.2%) 
2 resections: 14 patients (15.4%) 
3 resections: 1 patient (1.1%) 
4 resections: 3 patients (3.3%) 
 
 
Sex 
Males: 49 patients (53.8%) 
Females: 42 patients (46.2%) 
 
Smoking habits 
 
Current: 44 patients (48.4%) 
Ex: 21 patients (23.1%) 
Never: 26 patients (28.5%) 
 
 
Montreal classification (localization) 
L1 (ileal): 32 patients (35.2%) 
L2 (colonic): 16 patients (17.6%) 
L3 (ileocolonic): 35 patients (38.4%) 
L4 (upper): 8 patients (8.8%) 
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Montreal Classification (Behaviour) 
B1 (non-stenosing, non-
penetrating): 25 patients (27.5%) 
B2 (stenosing): 44 patients (48.3%) 
B3 (penetrating): 22 patients (24.2%) 
Perianal disease 
P (perianal disease): 33 patients 
(36.3%) 
CI = confident interval 
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Table 2. Comparison between azathioprine and adalimumab groups at T0 
Parameter adalimumab azathioprine p 
Age at the beginning of the 
drug (mean) 
45.1 years 39.6 years 0.806 
Years of disease before the 
start of the drug (median) 
13 years 5 years 0.056 
Sex 
Males 
17 patients 
(54.8%) 
32 patients 
(53.3%) 
0.892 
Females 
14 patients 
(45.2%) 
28 patients 
(47.6%) 
Smoking 
habits 
Current 
16 patients 
(51.6%) 
28 patients 
(46.7%) 
0.665 
Never or ex 
15 patients 
(48.4%) 
32 patients 
(53.3%) 
Surgical 
resections 
Never  
14 patients 
(45.2%) 
26 patients 
(43.3%) 
0.868 
Ever 
17 patients 
(54.8%) 
34 patients 
(56.7%) 
Biological 
drugs 
Naïve 
26 patients 
(83.9%) 
57 patients 
(95%) 
0.078 
Experienced 
5 patients 
(16.1%) 
3 patients 
(5%) 
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Disease 
localization 
Only small 
bowel 
11 patients 
(35.5%) 
24 patients 
(40%) 
0.676 
Colon 
involved 
20 patients 
(64.5%) 
36 patients 
(60%) 
History of 
perianal 
disease 
Yes 
14 patients 
(45.2%) 
19 patients 
(31.7%) 
0.207 
No 
17 patients 
(54.8%) 
41 patients 
(68.3%) 
HBI 
6 
95%CI: 5 - 8.4 
6.5 
95%CI: 5 – 8.1 
0,817 
 HBI = Harvey-Bradshaw index; CI = confident interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
Table 3. Progression in the specific Lémann Index subcategories 
Subcategory  Azathioprine  
T0 LI 
 
T1 LI 
p 
value 
Adalimumab 
T0 LI  
 
T1 LI 
p 
value 
S  1.6 2.1 0.03 1.3 1.3 0.125 
C  5.8 5.8 0.181 5.3 4.4 0.899 
U  N/A N/A N/A N/A N/A N/A 
P  N/A N/A N/A N/A N/A N/A 
T0 = before drug start; LI = Lémann Index; T1 = 1-year follow-up; S = small bowel; C = 
colon / rectum; U = upper tract; P = anal region; N/A = not applicable due to the low 
sample size of patients with damage in these locations. 
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Table 4. Predictors of response. 
Subcategory Azathioprine p 
value 
Adalimumab p 
value 
 Primary outcome 
reached 
Yes          No 
 Primary outcome 
reached 
Yes            No 
 
Disease duration 
(years, 95%CI) 
7 (1.0-17) 4 (2.6-7.4) 0.324 13 (2-15.9) 10.5 (4-20) 0.526 
Sex  
   male (n, %) 
   female (n, %) 
 
6/32 (18.8) 
11/28 (39.3) 
 
0.220 
 
10/17 (58.8) 
11/14 (78.6) 
 
0.246 
Smoking habits 
   active (n, %) 
   non-smoking  
   (n, %) 
 
6/28 (21.4) 
11/32 (34.4) 
 
0.271 
 
11/16 (68.7) 
10/15 (66.7) 
 
0.903 
Previous bowel 
resections 
   no (n, %) 
   yes (n, %) 
 
 
9/34 (26.5) 
8/26 (30.8) 
 
 
0.716 
 
 
14/17 (82.3) 
7/14 (50) 
 
 
0.059 
Biologic-naïve 
   yes (n, %) 
   no (n, %) 
 
N/A 
N/A 
 
N/A 
 
18/26 (69.2) 
3/5 (60%) 
 
0.690 
Perianal disease     
26 
 
   no (n, %) 
   yes (n, %) 
14/41 (34.1) 
3/19 (15.8) 
0.145 9/17 (52.9) 
12/14 (85.7) 
0.056 
CI = confidence interval; N/A = not applicable 
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Figure 1. Flow chart of the inclusion process of patients 
Figure 2. Comparison between adalimumab and azathioprine in reaching 
primary outcome (increase of Lémann Index after 12 months < 0.3 and drug not 
stopped and use of systemic corticosteroids for no more than 3 months) 
Figure 3. Progression of Lémann Index in the adalimumab group     
Figure 4. Progression of Lémann Index in the azathioprine group     
 
